CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 2896446
• 负责人: MARK R. GREEN
• 金额: $ 14.53万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-13 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2896446
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This grant application is submitted in support of the CALGB program at the Medical University of South Carolina (MUSC). MUSC has been a main member of CALGB only since July 1995. Yet already the Group Vice Chair, the Vice Chair of the CALGB Radiation Oncology Committee, the Chair of the CALGB Respiratory Committee, one phase III protocol chair, and four study co-chairs are MUSC faculty participants. Active MUSC programs in Experimental Therapeutics, Molecular Oncology, and Cancer Prevention and Control are involved in research activities of direct significance for CALGB based clinical and correlative projects to be proposed to the Group during the grant cycle covered by this application. Accrual to CALGB trials has been designated as the top institutional clinical trials priority by the Cancer Center Director at MUSC. A new CALGB affiliate relationship for the Ralph H. Johnson VA Medical Center in Charleston is being developed as of the Summer of 1997. This will contribute substantially to increased institutional accrual. Minority accrual at MUSC has always been more than double the CALGB average. It has ranged from a low of 25 percent in 1993 (when MUSC participated in CALGB as a Bowman Gray affiliate) to 36 percent in 1995. MUSC plans to participate in the NCI Minority accrual Initiative Program submitted as part of the CALGB Chairman's Central Office Grant. This initiative program and new programs between the Hollings Cancer Center at MUSC and the Charleston minority community, described in this application, should foster additional minority accrual. A CALGB audit at MUSC in September of 1996 was rated as excellent. The Medical University of South Carolina is an effective new Main Member in the Cancer and Leukemia Group B that is in a strong position to make important scientific, administrative, and accrual contribution to the Group during the five year period covered by this grant request.

描述（根据申请人的摘要改编）：此赠款申请 提交支持在医科大学的CALGB计划的支持 南卡罗来纳州（MUSC）。 MUSC自7月以来一直是Calgb的主要成员 1995年。但已经是团体副主席，Calgb的副主席 辐射肿瘤委员会，Calgb呼吸委员会主席， 一位III期协议主席和四个研究联合主席是MUSC教师 参与者。 实验疗法中的主动MUSC程序，分子 研究参与肿瘤学，预防癌症和控制 基于CALB的临床和相关性直接显着性的活动 在此所涵盖的赠款周期期间向小组提出的项目 应用。 对CalgB试验的应计被指定为顶级 癌症中心主任的机构临床试验优先 马斯克。 Ralph H. Johnson VA的新Calgb会员关系 截至1997年夏天，查尔斯顿的医疗中心正在开发。 这将有助于增加机构应计。 MUSC的少数族裔应比CLGB平均水平的两倍多。 它的范围从1993年的低25％（MUSC参加 Calgb作为Bowman Gray会员）至1995年的36％。MUSC计划 参加作为一部分提交的NCI少数族裔应计倡议计划 小牛董事长的中央办公室赠款。 这个计划计划和 MUSC的Hollings癌症中心与查尔斯顿之间的新计划 本申请中描述的少数民族社区应促进更多 少数派。 1996年9月在MUSC进行的CALB审核被评为 出色的。 南卡罗来纳州医科大学是一个有效的新 癌症和白血病B组的主要成员处于强大的位置 为了做出重要的科学，行政和应计贡献 该赠款请求涵盖的五年期间的小组。